TUESDAY, October 11, 12:00pm
Virtual via Zoom

Approach to Research and Therapy of ALL at MD Anderson in 2022

Blanche Tullman Lectureship in Hematology

Hagop M. Kantarjian, MD
Professor and Chair, Department of Leukemia, MD Anderson Cancer Center; Samsung Distinguished Leukemia Chair in Cancer Medicine, MD Anderson Cancer Center

Needs: Discuss a unique approach to research and therapy of ALL.
Objectives: Update results of novel strategies in Ph+ALL with ponatinib-blinatumomab, and in preB-ALL with chemotherapy + Inotuzumab-blinatumomab and review current therapies in ALL.

There is No Corporate Support for These Activities. Accreditation: The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Designation Statement: The Yale School of Medicine designates this live activity for 1 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Target Audience: YCC members, Smilow faculty, YSM, Nursing, Public Health Students. Faculty Disclosures: Winer—nothing to disclose. Kantarjian—Honoraria-Amgen, Abbvie, Astellas, Amphista, Ascentage, Ipsen, Novartis, Pfizer. Grant or research support-Abbvie, Amgen, Ascentage, Bristol Myers Squibb, Daiichi-Sankyo, Immunogen, Novartis, Jazz. All of the relevant financial relationships listed for these individuals have been mitigated.

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. Mitigation of Financial Relationships Statement: Yale CME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.